ISHLT Voices

ISHLT

ISHLT Voices features conversations, studies, and member profiles. Explore advanced heart and lung failure, transplantation, mechanical circulatory support, and pulmonary vascular disease through the eyes of your community. The content of industry-supported ISHLT Voices podcasts are developed entirely by our industry partners. They are not official ISHLT educational programs, and therefore are not eligible for CME under the ISHLT. read less
ScienceScience
Start Here
Trio of Insights: Commentary on the TRIFECTA Studies Analyzing Three Rejection Diagnostic Tools in Heart, Lung, and Kidney Transplantation, From Natera
15-12-2023
Trio of Insights: Commentary on the TRIFECTA Studies Analyzing Three Rejection Diagnostic Tools in Heart, Lung, and Kidney Transplantation, From Natera
Presented by Natera Natera returns with another ISHLT Voices podcast. Post-transplant monitoring with noninvasive donor derived cell free DNA (dd-cfDNA) has been growing in popularity and usage with several transplant centers significantly reducing surveillance biopsies in favor of a single blood test. But, as with all new technology, there are outstanding questions to understand how and why the technology works as well as it does. In this episode, leading investigators from the Alberta Transplant Applied Genomics Centre (ATAGC), Drs. Phil Halloran, Kieran Halloran, and Patrick Gauthier will walk you through their efforts in the TRIFECTA series of studies to triangulate insights from dd-cfDNA, molecular diagnostics, and donor specific antibody versus standard histological assessments in heart, lung, and kidney transplantation. Philip F. Halloran, MD, PhD, FRCP(C), OC, FRSC Professor of Medicine & Medical Microbiology and Immunology Director, Alberta Transplant Applied Genomics Centre University of Alberta Edmonton, AB Canada Kieran Halloran, MD, MSc Transplant Pulmonologist Associate Professor University of Alberta Edmonton, AB Canada Patrick Gauthier, PhD Senior Data Scientist Alberta Transplant Applied Genomics Centre Edmonton, AB Canada   This episode was created for ISHLT Voices and sponsored by Natera. The content of this podcast was developed entirely by our industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.

Episodes

Trio of Insights: Commentary on the TRIFECTA Studies Analyzing Three Rejection Diagnostic Tools in Heart, Lung, and Kidney Transplantation, From Natera
15-12-2023
Trio of Insights: Commentary on the TRIFECTA Studies Analyzing Three Rejection Diagnostic Tools in Heart, Lung, and Kidney Transplantation, From Natera
Presented by Natera Natera returns with another ISHLT Voices podcast. Post-transplant monitoring with noninvasive donor derived cell free DNA (dd-cfDNA) has been growing in popularity and usage with several transplant centers significantly reducing surveillance biopsies in favor of a single blood test. But, as with all new technology, there are outstanding questions to understand how and why the technology works as well as it does. In this episode, leading investigators from the Alberta Transplant Applied Genomics Centre (ATAGC), Drs. Phil Halloran, Kieran Halloran, and Patrick Gauthier will walk you through their efforts in the TRIFECTA series of studies to triangulate insights from dd-cfDNA, molecular diagnostics, and donor specific antibody versus standard histological assessments in heart, lung, and kidney transplantation. Philip F. Halloran, MD, PhD, FRCP(C), OC, FRSC Professor of Medicine & Medical Microbiology and Immunology Director, Alberta Transplant Applied Genomics Centre University of Alberta Edmonton, AB Canada Kieran Halloran, MD, MSc Transplant Pulmonologist Associate Professor University of Alberta Edmonton, AB Canada Patrick Gauthier, PhD Senior Data Scientist Alberta Transplant Applied Genomics Centre Edmonton, AB Canada   This episode was created for ISHLT Voices and sponsored by Natera. The content of this podcast was developed entirely by our industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.
Experts Tackle Bronchiolitis Obliterans Syndrome Part Three, From Zambon USA
15-11-2023
Experts Tackle Bronchiolitis Obliterans Syndrome Part Three, From Zambon USA
Presented by Zambon USA ISHLT Voices returns with another podcast presented by Zambon USA exploring bronchiolitis obliterans syndrome (BOS). BOS is one of the most common forms of chronic lung transplant rejection, and in part three of this series, experts take a deep dive into CLAD phenotype differentiation, current gaps in diagnosis and management of BOS, emerging treatment strategies, and lastly, discuss the advances made in BOS diagnosis and management over the last decade. Steven Hays, MD Medical Director, Advanced Lung Disease and Lung Transplant Programs University of California, San Francisco San Francisco, CA USA Justin P. Rosenheck, DO Clinical Assistant Professor of Internal Medicine Division of Pulmonary, Critical Care and Sleep Medicine, Lung Transplant Program The Ohio State University Wexner Medical Center Columbus, OH USA This episode was created for ISHLT Voices and sponsored by Zambon USA, Ltd. The content of this industry-supported ISHLT Voices podcast is developed entirely by our industry partner, Zambon. This is not an official ISHLT educational program, and therefore is not eligible for CME under the ISHLT.
Exploratory Evidence Supports Use of Donor-Derived Cell-Free DNA to Monitor Pediatric Heart Transplant Recipients, From Natera
18-10-2023
Exploratory Evidence Supports Use of Donor-Derived Cell-Free DNA to Monitor Pediatric Heart Transplant Recipients, From Natera
Presented by Natera In this episode of the ISHLT Voices podcast, Dr. Shri Deshpande, a cardiologist at the National Children’s Hospital in Washington, DC USA, discusses his work on improving the care of pediatric heart transplant patients.  Dr. Deshpande's research focuses on the use of cell-free DNA in monitoring transplant recipients for rejection. He explains that cell-free DNA, released when cells break down, can be detected in the bloodstream and used as a non-invasive screening tool to assess the health of transplanted organs.  The discussion covers the external validation of the Prospera™ assay by Natera, which has shown high negative predictive value and specificity, making it a promising tool for reducing the need for invasive biopsies and improving long-term transplant outcomes. Dr. Deshpande also highlights the potential for wider implementation of this technology in standard transplant care and ongoing research to optimize its use. Shriprasad Deshpande, MD Cardiologist Director, Advanced Cardiac Therapies Director, Heart Transplant Program National Children’s Hospital Washington, DC USA   This episode was created for ISHLT Voices and sponsored by Natera. The content of this podcast was developed entirely by our industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.
Experts Tackle Bronchiolitis Obliterans Syndrome Part Two, From Zambon USA
20-09-2023
Experts Tackle Bronchiolitis Obliterans Syndrome Part Two, From Zambon USA
Presented by Zambon USA ISHLT Voices returns with another podcast presented by Zambon USA exploring bronchiolitis obliterans syndrome (BOS). BOS is one of the most common forms of chronic lung transplant rejection, and in part two of this series, experts take a deep dive into the role of lung function monitoring post-transplant for the detection of chronic lung transplant rejection, specifically BOS. Shambhu Aryal, MD Medical Director, Lung Transplant Program Director, Sarcoidosis Clinic Inova Health System Falls Church, VA USA Justin P. Rosenheck, DO Clinical Assistant Professor of Internal Medicine Division of Pulmonary, Critical Care and Sleep Medicine, Lung Transplant Program The Ohio State University Wexner Medical Center Columbus, OH USA Drs. Aryal and Rosenheck discuss the current status of diagnostic techniques for BOS, the relevance to patient quality of life, and unmet needs and future approaches to BOS diagnosis and monitoring.  This episode was created for ISHLT Voices and sponsored by Zambon USA, Ltd. The content of industry-supported ISHLT Voices podcasts are developed entirely by our industry partners. They are not official ISHLT educational programs, and therefore are not eligible for CME under the ISHLT.
The Future of Bronchiolitis Obliterans Syndrome, From Zambon USA
12-07-2022
The Future of Bronchiolitis Obliterans Syndrome, From Zambon USA
Presented by Zambon USA The first episode of ISHLT Voices is now live! This podcast, presented by Zambon USA, explores bronchiolitis obliterans syndrome (BOS), one of the most common forms of chronic lung transplant rejection. Despite advances in surgical techniques, BOS remains the Achilles heel of lung transplants. In this podcast, experts address critical questions regarding diagnosis, management, and future approaches for BOS. Shambhu Aryal, MDMedical Director, Lung Transplant Program Director, Sarcoidosis Clinic Inova Health System Falls Church, VA USA Howard J. Huang, MDChief, Section of Lung Transplantation Medical Director, Houston Methodist Lung Transplant Center Houston Methodist Hospital Houston, TX USA Drs. Aryal and Huang discuss the current status of managing BOS patients, including detection, diagnosis, and treatment, as well as unmet needs and future approaches to managing the condition.  This episode was created for ISHLT Voices and sponsored by Zambon USA, Ltd. The content of industry-supported ISHLT Voices podcasts are developed entirely by our industry partners. They are not official ISHLT educational programs, and therefore are not eligible for CME under the ISHLT.